COMBAT-MS is a research project financed by PCORI
Rituximab in multiple sclerosis: A comparative study on effectiveness, safety, and patient reported outcomes
PI: Fredrik Piehl, MS neurologist, professor
Karolinska University Hospital and Karolinska Institutet
Stockholm Sweden
Photo: N/A
The objectives of COMBAT-MS is to compare rituximab (RTX) and other disease-modifying treatments (DMTs) regarding efficacy, safety, tolerability, and patient satisfaction.
We will study:
- How RTX compare with other DMTs in patients who have had continued disease activity on a previous DMT
- How does RTX compare with other DMTs in patients faced with choosing their first MS medication